TNM001 / Guangzhou Trinomab Biotechnology - LARVOL DELTA

Genetic variability of respiratory syncytial virus and its impact on monoclonal antibody binding sites: a national cross-sectional study during the 2023-2024 season. (PubMed, Int Immunopharmacol) - "This study provides a critical genomic snapshot of RSV in Italy prior to the introduction of vaccines and mAbs. Continuous surveillance is essential for monitoring viral evolution and supporting the long-term effectiveness of future immunization strategies."

Clinical • Journal • Observational data • Infectious Disease • Influenza • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants (clinicaltrials.gov) - P3 | N=201 | Not yet recruiting | Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd.

New P3 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study of TNM001 in Chinese Healthy Preterm and Term Infants (clinicaltrials.gov) - P1/2 | N=31 | Completed | Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ Jun 2023 | Trial primary completion date: Dec 2023 ➔ Jun 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants (clinicaltrials.gov) - P2b | N=2250 | Not yet recruiting | Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd.

New P2b trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study of TNM001 in Chinese Healthy Preterm and Term Infants (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Trinomab Biotech Co., Ltd.

New P1/2 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections